Coorte nacional prospectiva no Chile mostrou que a efetividade da CoronaVac foi de 65,9% para Covid-19 sintomática, 87,5% para hospitalizações, 90,3% para admissões em UTI e 86,3% para mortes.

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile – New England Journal of Medicine

Relacionado: Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years. E WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic. E Brazilian town experiment shows mass vaccination can wipe out COVID-19.

Comentário no Twitter

Chile's data on Sinovac CoronaVac in NEJM: not controlled study. Model details pic 2
– doses 28 days apart (like Serrana trial)
– symptomatic disease 65.9% (65-67)
– hospitalization 87.5% (87-88)
– intensive care 90.3% (89-91)
– Covid death 86.3% (85-88)
https://t.co/CB1U8Ar163 pic.twitter.com/4HwASRCnwQ

— Hilda Bastian, PhD (@hildabast) July 7, 2021